Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Increased Body Temperature01:25

Increased Body Temperature

7.7K
A body temperature above  38°C  (100.4 °F) is known as fever or pyrexia, and a person with fever is termed 'febrile.' Typically, the hypothalamus, a part of the brain that acts as the body's thermostat, regulates body temperature through a thermoregulatory setpoint. It receives signals from cold and warm thermal receptors throughout the body and adjusts the body's temperature accordingly. Fever occurs when this hypothalamic setpoint is altered, usually in...
7.7K
Homeostatic Imbalances in Body Temperature01:19

Homeostatic Imbalances in Body Temperature

4.4K
Hyperthermia occurs when the body's temperature becomes unusually high, often due to heat exposure, intense physical activity, or certain illnesses. This condition can create a dangerous cycle where elevated body temperature increases the metabolic rate, generating more heat and potentially leading to organ failure and brain damage. A severe form of hyperthermia, called heat stroke, can raise body temperature to life-threatening levels. Fever, on the other hand, is a controlled form of...
4.4K
Types of Fever01:25

Types of Fever

1.4K
Fever can be triggered by several factors, including infections, nervous system disorders, certain cancers, blood diseases like leukemia, embolism, thrombosis, heatstroke, dehydration, surgical trauma, crushing injuries, and allergic reactions.
Here are the different types of fever:
1.4K
Methods of reducing fever01:22

Methods of reducing fever

1.6K
The signs and symptoms of fever include hot and dry skin, flushed face, thirst, muscle aches, anorexia, headache, tachycardia, tachypnea, and fatigue. Elevated body temperature is reduced using two methods: pharmacological and nonpharmacological. Proper identification and treatment of the root cause of a fever is of utmost importance.
Pharmacological Methods of Reducing Fever:
1.6K
Decreased Body Temperature01:29

Decreased Body Temperature

1.2K
A decreased body temperature can occur in patients with hypothermia and frostbite. Heat loss with extended cold exposure overpowers the body's ability to create heat, resulting in hypothermia. Core temperature readings help classify hypothermia. Mild hypothermia is temperatures between 32 °C (89.6 °F) and 35°C (95 °F) and is caused by impaired thermoregulation. Moderate hypothermia is temperatures between 28 C (82.4 °F) and 32 °C (89.6 °F) caused by...
1.2K
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

1.2K
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
1.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: residual risk after familial RYR1 testing: interpreting malignant hyperthermia susceptibility in the context of regional testing strategies.

European journal of human genetics : EJHG·2026
Same author

EMQN Best Practice Guidelines for Genetic Testing and Reporting in RYR1-related disorders.

European journal of human genetics : EJHG·2026
Same author

Reply by Authors.

The Journal of urology·2026
Same author

Corrigendum to 'Functional analysis of RYR1 variants in Australian and New Zealand patients at risk of susceptibility to malignant hyperthermia' (Br J Anaesth 2026; 136: 323-32).

British journal of anaesthesia·2026
Same author

European Malignant Hyperthermia Group 2025 guidelines for the investigation of malignant hyperthermia susceptibility.

British journal of anaesthesia·2026
Same author

Functional analysis of RYR1 variants in Australian and New Zealand patients at risk of susceptibility to malignant hyperthermia.

British journal of anaesthesia·2025
Same journal

Care of patients with Phenylketonuria (PKU) in Germany - a claims data analysis from 2013 to 2023.

Orphanet journal of rare diseases·2026
Same journal

A lifespan pooled analysis of 832 cases: characterizing the lifespan profile of clinical presentations and comorbidities in congenital pulmonary airway malformation.

Orphanet journal of rare diseases·2026
Same journal

Mortality trends and socioeconomic inequalities in sickle cell disease in Colombia, 2012-2023: a population-based study.

Orphanet journal of rare diseases·2026
Same journal

Mitochondrial stress markers associate with phenotypic variability in Fabry disease.

Orphanet journal of rare diseases·2026
Same journal

Preclinical modeling of Loeys-Dietz syndrome: insights into mechanisms and therapy.

Orphanet journal of rare diseases·2026
Same journal

Fatigue and pain in children with multiple osteochondromas: a cross-sectional study.

Orphanet journal of rare diseases·2026
See all related articles

Related Experiment Video

Updated: Apr 6, 2026

Protocol for Long Duration Whole Body Hyperthermia in Mice
07:56

Protocol for Long Duration Whole Body Hyperthermia in Mice

Published on: August 25, 2012

12.1K

Malignant hyperthermia: a review.

Henry Rosenberg1, Neil Pollock2, Anja Schiemann3

  • 1Department of Medical Education and Clinical Research, Saint Barnabas Medical Center, Livingston, NJ, 07039, USA. HRosenberg@barnabashealth.org.

Orphanet Journal of Rare Diseases
|August 5, 2015
PubMed
Summary
This summary is machine-generated.

Malignant hyperthermia (MH) is a serious genetic disorder triggered by anesthesia, causing a dangerous hypermetabolic state. Early diagnosis and dantrolene sodium treatment are crucial for survival.

More Related Videos

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K
Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management
06:43

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Published on: November 21, 2017

25.3K

Related Experiment Videos

Last Updated: Apr 6, 2026

Protocol for Long Duration Whole Body Hyperthermia in Mice
07:56

Protocol for Long Duration Whole Body Hyperthermia in Mice

Published on: August 25, 2012

12.1K
Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
13:41

Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model

Published on: January 13, 2023

3.0K
Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management
06:43

Esophageal Heat Transfer for Patient Temperature Control and Targeted Temperature Management

Published on: November 21, 2017

25.3K

Area of Science:

  • Pharmacogenetics
  • Skeletal Muscle Physiology
  • Anesthesiology

Background:

  • Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle, presenting as a hypermetabolic response to specific anesthetic agents and muscle relaxants.
  • MH reactions occur in 1:10,000 to 1:250,000 anesthetics, but genetic susceptibility may be as high as 1 in 400 individuals.
  • The syndrome affects humans, certain breeds of pigs, dogs, and horses, with classic signs including hyperthermia, tachycardia, acidosis, and muscle rigidity.

Purpose of the Study:

  • To summarize the understanding of malignant hyperthermia (MH), a pharmacogenetic disorder of skeletal muscle.
  • To highlight the pathophysiology, diagnosis, genetic basis, and treatment of MH.
  • To emphasize the importance of dantrolene sodium and improved clinical management in reducing MH mortality.

Main Methods:

  • Review of clinical manifestations, including hyperthermia, tachycardia, tachypnea, increased CO2 production, acidosis, hyperkalemia, muscle rigidity, and rhabdomyolysis.
  • Investigation of the genetic basis, primarily defects in the ryanodine receptor (RYR1 gene), with over 400 variants identified.
  • Description of diagnostic testing, including in vitro muscle contracture response and DNA testing for MH susceptibility.

Main Results:

  • The syndrome is caused by an uncontrolled rise in myoplasmic calcium, primarily due to RYR1 gene defects.
  • Diagnostic advancements, including genetic testing, have improved susceptibility identification.
  • Mortality rates have significantly decreased from 80% to less than 5% due to increased understanding and improved treatment.

Conclusions:

  • Malignant hyperthermia (MH) is a life-threatening but treatable genetic disorder.
  • Dantrolene sodium is a specific antagonist and must be readily available during general anesthesia.
  • Continued research and clinical vigilance are essential for managing MH and improving patient outcomes.